Sharekhan

Venus Remedies Ltd

Thu 13/03/2025,15:48:1 | NSE : VENUSREM

₹ 290.40-0.35 (-0.12%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 290.40

Previous Close

₹ 290.75

Volume

21600

Mkt Cap ( Rs. Cr)

₹388.18

High

₹ 294.65

Low

₹ 289.90

52 Week High

₹ 427.90

52 Week Low

₹ 270.25

Book Value Per Share

₹ 369.73

Dividend Yield

0.00

Face Value

₹ 10.00

What’s Your Call?

Collective community sentiment on Venus Remedies Ltd

Your Vote -

Buy

43.75%

Hold

18.75%

Sell

37.50%

43.75%

16 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

100%

Sell Order Quantity

0%

Bid Price

Qty

234.30

3500

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

3500

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Option Chain

Analyzes market sentiment, predicts Venus Remedies Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Venus Remedies receives marketing nod for Sugammadex in Philippines

    4 Mar 2025, 1:15PM Venus Remedies announced on Tuesday that it has received marketing authorization from Philippine authorities for Sugammadex, a medication used to reve
  • Venus Remedies L - Updates

    25 Feb 2025, 10:13AM Venus Remedies Limited has informed the Exchange regarding ' Venus Remedies Secures Exclusive In-Licensing Rights from Infex Therapeutics to Develop a
  • Venus Remedies L - Venus Remedies Secures Exclusive In-Licensing Rights From Infex Therapeutics To Develop And Commercialize

    25 Feb 2025, 10:09AM Venus Remedies secures exclusive In-Licensing rights from Infex Therapeutics to develop and commercialize MET-X in India
  • Venus Remedies gets market authorization for anticoagulant from Indonesia

    10 Feb 2025, 6:28PM Pharma major Venus Remedies on Monday said it has received marketing authorization from Indonesia for its Enoxaparin, an anticoagulant, in pre-filled
  • Venus Remedies L - Updates

    10 Feb 2025, 1:03PM Venus Remedies Limited has informed the Exchange regarding 'Venus Remedies gets Marketing Authorization for anticoagulant Enoxaparin from Indonesia
  • Venus Remedies L - Venus Remedies Gets Market Authorization For Anticoagulant Enoxaparin From Indonesia

    10 Feb 2025, 12:50PM Venus Remedies gets Market Authorization for anticoagulant Enoxaparin from Indonesia
  • Venus Remedies L - Copy of Newspaper Publication

    6 Feb 2025, 1:24PM Venus Remedies Limited has informed the Exchange about Copy of Newspaper Publication
  • Venus Remedies L - Integrated Filing- Financial

    5 Feb 2025, 6:48PM Integrated Filing of Unaudited Financial results for the period ended on 31st December 2024.
  • Venus Remedies L - Integrated Filing (Financial)

    5 Feb 2025, 6:38PM Integrated filing of Unaudited Financial results for the period ended on 31st December 2024.
  • Venus Remedies L - Updates

    4 Feb 2025, 9:27PM Venus Remedies Limited has informed the Exchange regarding ''Intimation under Regulation 30
  • Venus Remedies L - Intimation Under Regulation 30

    4 Feb 2025, 9:17PM Intimation under Regulation 30
  • Venus Remedies L Q3 net profit zooms 194.02% at Rs 24.08 cr

    4 Feb 2025, 9:12PM The company reported standalone net profit of Rs 24.08 crore for the quarter ended December 31, 2024 as compared to Rs 8.19 crore in the same period l
  • Venus Remedies L - Unaudited Financial Results As On 31.12.2024

    4 Feb 2025, 9:04PM Unaudited financial results as on 31.12.2024
  • Venus Remedies L - Financial Result Updates

    4 Feb 2025, 8:55PM Venus Remedies Limited has submitted to the Exchange, the financial results for the period ended December 31, 2024.
  • Venus Remedies L - Outcome of Board Meeting

    4 Feb 2025, 8:53PM Venus Remedies Limited has informed the Exchange regarding Board meeting held on February 04, 2025.
  • Venus Remedies L - Board Meeting Intimation

    24 Jan 2025, 6:31PM VENUS REMEDIES LIMITED has informed the Exchange about Board Meeting to be held on 04-Feb-2025 to inter-alia consider and approve the Unaudited Financ
  • Venus Remedies L - Board Meeting Intimation for Board Meeting Scheduled To Be Held On 04Th February 2025

    24 Jan 2025, 6:18PM VENUS REMEDIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/02/2025 ,inter alia, to consider and
  • Venus Remedies L - Updates

    20 Jan 2025, 5:04PM Venus Remedies Limited has informed the Exchange regarding 'Venus RemediesLimited successfullrenews EU GMP Certification'.
  • Venus Remedies L - Venus Remedies Limited Successfully Renews EU GMP

    20 Jan 2025, 4:42PM Venus Remedies Limited successfully renews EU GMP
  • Venus Remedies L - Updates

    7 Jan 2025, 8:13PM Venus Remedies Limited has informed the Exchange regarding 'Compliance under REg 74(5) of SEBI DP regulations'.
  • Venus Remedies L - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    7 Jan 2025, 8:03PM Compliance under reg 74(5) of SEBI DP regulations.
  • Venus Remedies L - Trading Window-XBRL

    1 Jan 2025, 12:48PM VENUS REMEDIES LIMITED has informed the Exchange about Closure of Trading Window
  • Venus Remedies L - Updates

    31 Dec 2024, 1:03PM Venus Remedies Limited has informed the Exchange regarding 'Venus Remedies Expands Reach in Eastern European market with accreditation of Good Manufa
  • Venus Remedies L - Venus Remedies Limited Expands Reach In Eastern European Market With Accreditation Of Good Manufacturing

    31 Dec 2024, 1:08PM Venus Remedies Limited expands reach in Eastern European market with accreditation of Good Manufacturing Practice (GMP) certification from Ministry of
  • Venus Remedies L - Trading Window

    26 Dec 2024, 5:39PM Venus Remedies Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2
  • Venus Remedies L - Payment Of SOP Fine

    18 Dec 2024, 7:26PM Payment of SOP fine
  • Venus Remedies L - General Updates

    18 Dec 2024, 7:23PM Venus Remedies Limited has informed the Exchange about payment of SOP fine
  • Venus Remedies secures Marketing Authorization in Philippines

    6 Dec 2024 , 2:55PM Pemetrexed is a type of chemotherapy used in the treatment of lung cancer
  • Venus Remedies achieves major milestone with UNICEF

    13 Jun 2024 , 2:04PM Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product.
  • Venus Remedies gets new marketing nod for two drugs in Europe

    12 Jan 2024 , 12:38PM Venus Remedies gets new marketing authorisations for Docetaxel & Gemcitabine from Malta, Europe
  • Venus Remedies secures marketing authorisations for Docetaxel and Cytarabine

    21 Dec 2023 , 2:22PM Venus Remedies achieves marketing authorizations for Docetaxel in Israel and Cytarabine in Colombia
  • Venus Remedies Consumer Healthcare Division, R3SET forays into wellness segment

    20 Dec 2023 , 12:03PM Venus Remedies R3SET takes strategic lap into wellness with holistic health Innovations
  • Venus Remedies receives market authorisations for Enoxaparin in Azerbaijan

    5 Dec 2023 , 11:37AM Enoxaparin is used to prevent and treat harmful blood clots
  • Venus Remedies grant market authorisations in Saudi Arabia and Philippines

    1 Dec 2023 , 12:19PM Venus Remedies gets marketing authorisations for Paclitaxel & Zolendronic acid in the Philippines & for Bleomycin 15lU in Saudi Arabia
  • Venus Remedies arm gets authorization to market Cancer Drug in UK

    26 Oct 2023 , 11:40AM Venus Remedies granted martket authorisation for Bleomycin 15000 IU in UK
  • Venus Remedies gets marketing nod for six chemotherapy drugs from Philippines

    16 Oct 2023 , 10:46AM Secures 525 marketing approvals for its oneology products across 76 Countries.
  • Venus Remedies extends its oncology portfolio in South Eastern Europe

    20 Sep 2023 , 10:48AM Venus Remedies gets Serbian marketing nod for Gemcitabine & Docetaxel, extends oncology portfolio in South Eastern Europe
  • Venus Remedies on expansion spree in Gulf

    28 Aug 2023 , 12:25PM Venus Remedies gets marketing approval from Saudi Arabia for its product Enoxaparin in pre-filled syringes
  • Venus Remedies oncology wing product registration go upto 506

    31 Jul 2023 , 11:23AM Venus Remedies gets marketing nod for cancer drugs from Philippines, Paraguay, Georgia & Moldova
  • Venus Remedies gets marketing nod for chemo drug.

    5 Jul 2023 , 12:55PM Venus Remedies gets marketing nod from Oman, Malaysia, Bosnia & Trinidad & Tobago for chemo drug
  • Venus Remedies bags nod to market Meropenem, its block buster generic drug, in Spain

    22 Jun 2023 , 11:43AM Venus Remedies German arm gets Spanish regulator nod to market Meropenem, a broad-spectrum antibiotic in Spain
  • Venus Remedies gets Ukrainian GMP nod

    7 Jun 2023 , 11:22AM Venus Remedies gets Ukrainian GMP nod for its Carbapenem, Oncology parenteral facilities
  • Venus Remedies bags Saudi GMP nod for all its production facilities

    27 Feb 2023 , 10:12AM Venus Remedies gets Saudi GMP nod for all its production facilities in Baddi.
  • Venus Remedies

    9 Dec 2021 , 11:31AM Venus Remedies: Gets approval from the Government of India for PLI scheme. The company has received an approval under category C of the PLI scheme and is eligible for incentives for FY2022-23 to FY2027-28 subject to fulfilment of minimum investment criteria and based on incremental sales of eligible products as per the scheme guidelines, Hence Positive.
  • Venus Remedies enters into partnership with West Pharmaceutical Service

    13 Apr 2021 , 1:29PM Venus Remedies enters into partnership with West Pharmaceutical Services to Launch Cloti-Xa (Enoxaparin Prefilled Syringes) in India

Key fundamentals

Evaluate the intrinsic value of Venus Remedies Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 547.2703 516.7264 488.0923 447.7034 485.9376
Liabilities 547.2703 516.7264 488.0923 447.7034 485.9376
Equity 13.367 13.367 13.367 12.342 12.342
Gross Profit 60.8913 61.5258 68.8218 46.8627 43.067
Net Profit 30.5004 28.9644 48.9866 54.2724 -8.2269
Cash From Operating Activities 35.3826 28.0548 40.8998 132.6673 77.1527
NPM(%) 5.3 5.38 8.51 10.54 -2.56
Revenue 575.2124 537.6619 575.181 514.623 320.2307
Expenses 514.3211 476.1361 506.3592 467.7603 277.1637
ROE(%) 6.17 5.86 9.91 10.98 -1.66

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
3 30 0 279.5
23 Sep 2013 3 30 0 304.45
20 Sep 2012 3 30 0 228.05
22 Sep 2011 3 30 0 253.15
23 Sep 2010 3 30 0 268
17 Sep 2009 3 30 0 278.45
12 Sep 2008 4 40 0 400.85
18 Sep 2007 3 30 0 470.05

Peers

Other companies within the same industry or sector that are comparable to Venus Remedies Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 808.20 -1.14 11.41 165.94 1321.50 1.42
Lotus Eye Hospital and Institute Ltd 57.06 -0.77 237.75 604.65 14.01 0.88
Vaishali Pharma Ltd 12.12 -5.90 606.00 311.66 2.31 0.00
Astec Lifesciences Ltd 653.90 -5.55 0.00 570.14 -239.30 0.00

Company Info

M/s VENUS REMEDIES LTD. was incorporated as a private limited company on 15th day of Sept. 1989 in the name and style of Venus Glucose Pvt Ltd, and subsequently converted into a public limited company, vide fresh certificate of incorporation dated 19th Sept. 1994 and the name was converted as "Venus Remedies Ltd" under the Companies Act, issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh at Jalandhar. The company started its production in the year 1991 with Intravenous/Intramuscular (IV/IM) injectable forms at its running unit located at 52, Ind. Area. Phase-I, Panchkula Distt. Ambala (Haryana). Subsequently the company introduced Eye/Ear/Nasal Drops during the year 1994. During the same year, the company also expanded its existing capacity from 9 lacs pieces per annum to 15 lacs pieces per annum and that of 9 lacs pieces to 20 lacs pieces per annum of IV fluids section and vial section respectively. And, during 1994, the company has also certified as "WHO-GMP" (Good practices in manufacturing and quality control) as specified by WHO, Geneva by the State Drug Controller of Haryana. MAIN OBJECTS OF THE COMPANY The main objects of the company as set out in its Memorandum of Association are : 1. To manufacture, import, export of intravenous transfusion fluids and formations such as dextrose, dextrose with sodium chloride, normal saline, isolate P, isolate M, isolate G, isolate E, Mannitol etc. in various concentrations, intravenous solution for dialysis purposes, ACD Sterile bottles for blood collections, pharmaceutical parenteral preparations like Aminophylline, Adernaline, Water for injection, Chloroquine Sulphate, Sodium bi-carbonate, Analgin, Diazepam, Oxyphenbutazone & other injectables. 2. To carry on the business of deriving, formulating, purchasing, producing manufacturing, preparing, processing, mising, compounding, refining, marketing, distributing, selling and trading in pharmaceuticals, Chemicals, cosmetics, perfumes, medicines and drugs of all kinds, specifications and descriptions, and to do so especially in respect of all kinds of analgesics and antipyretics. 3. To carry on the business of purchasing, producing manufacturing, preparing, processing, mixing, compounding, refining, marketing, distributing, selling and trading in all classes and kinds of raw material ingredients, mixtures, compounds and derivatives connected to, intermediate in or associated with the manufacture production and sale of pharmaceuticals, chemicals medicines and drugs. 4. To carry on the business of vialling, bottling, packing. repacking and processing of capsules, syrups, tablets, injectables, aerosoles and ointment, bulk drugs and chemicals. 2005 -Venus Remedies successfully launches its Brand "Ronem" -Venus Remedies announces Strategic Marketing tie up with M/S Cadila Pharmaceuticals Ltd - M/s Themis Medicare Ltd enters into a Strategic Marketing Tie Up with Venus Remedies Ltd. -Delist equity shares from Delhi, Jaipur & Ahmedabad Stock Exchanges. -Venus Remedies has entered into Strategic Marketing Agreement with Merck Specialties Pvt Ltd, a wholly owned Subsidiary of Merck Ltd, Darmstadt, Germany, for its Oncology range of products. -Venus Remedies sets up a wholly owned subsidiary in Germany 2006 -Venus Remedies Ltd has informed that a Company has been granted three prestigious ISO certifications -Venus Remedies in-licenses product Technology from USA 2007 -Venus Remedies Ltd has signed an agreement with M/s. Pharma Match R&D B.V. a limited Company based at Amsterdam, Netherlands for jointly preparing, registering and marketing an EU E-CTD Dossier for a latest generation Carbapenem Injectible. 2008 -Venus facilities Accredited with European GMP Certification. -Venus Remedies Ltd has informed that the Company's manufacturing facilities have been approved by the G.F.T.O of Syria for manufacturing and exporting its products to Syria. -Venus Remedies - European AMP Accreditation for Venus Oncology Facilities. -Venus Remedies Ltd has informed that the Company has successfully launched its fourth Research Product, a Fixed Dose Combination of Cephalosporin with aminoglycoside under the Brand name "TOBRACEF" in Domestic Market for the first time globally. 2009 -Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa. -Venus Bags Another Product Patent from South Africa for POTENTOX. --Registered Office of the Company has been shifted from SCO 39, Sector 26, Chandigarh. to SCO 857, C. No. 10, IInd Floor, NAC Manimajra, Chandigarh - 160 101. 2010 -Venus Remedies Ltd, a fast-growing pharmaceutical company in the country, has launched MEBATIC, a unique antibiotic combination in infusion form to cure severe gastro intestinal (GI) infections. -"Venus Remedies receives GMP Certification from Botswana". -Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits. -The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015. -Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent". 2011 -"Venus Remedies Anti-Cancer drug "GEMCITABINE" gets UK MHRA approval". -"Sulbactomax" patent from Mexico strengthens Venus Remedies' presence in Latin America". -"Venus Remedies successfully completes Phase I & II Clinical Trials of TUMATREK (VRP162O), cancer detection molecule". -Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011. -"Venus launches its patented research product ACHNIL" in India". -"Venus Remedies wins "India Manufacturing Excellence Award 2011". 2012 -VenusRemedis - Venus's ACHNIL, BioSpectrum Product of the Year 2012. -VenusRemedis - Innovative Solution for alleviating cancer. -"Venus Remedies introduces "Ready-to-Use" Single Vial Taxedol in India". -Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India -The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012". -"Venus wins Patent award in Silver Category". 2013 -"Venus Remedies launches Elores - CSE 1034, a US Patent projected product in India". -"Venus Remedies signs MoU for Elores with South African pharmaceutical firm". -"Venus Remedies takes its flagship product, Elores into Latin America". -"Venus launches its first OTC product Ezenus". -"Venus sign Exclusive Marketing Rights deal for its novel Antibiotic Ajuvant Entity to South Africas second largest Pharmaceutical Company - Adcock". -"Venus Remedies MEROPENEM receives market authorization in Mexico". -Venus Remedies Ltd has informed regarding "ELORES awarded Gold Medal for being the best Innovation of 2013" -"Venus wins Innovative 100 Award for ELORES". -"Venus bags UBM India Pharma Award for Elores". 2014 -"Venus ties up with Mylan for marketing meropenem in three European countries". - "VMRC Drug VRP008 to Fight "MULTI-DRUG Resistant Bacteria" Receives European Patent". -"Venus Receives Market Authorization for Meropenem from SWITZERLAND (SWISSMEDIC)". 2015 -"Venus announces issuance of Indian Patent for Vancoplus". -Venus Remedies holds blood, organ donation camps on its Panchkula premises. 2016 -"Venus launches its second OTC product "SWATCH GAURD" a herbal Hand Sanitizer". 2019 -"Venus announces deal with Cipla for its patented product Elores for Indian Territory". 2021 -Venus Remedies launched its full-fledged Consumer Healthcare Division. -Venus Remedies Limited has been selected for Production Linked Incentive Scheme (PLI) of the Government of India. 2022 -Venus Remedies won WHO Good Distribution Practices (GDP) certification for quality services across entire supply chain. -Venus remedies wins ambitionbox best places to work award. -Venus Remedies Limited has been Great Place to Work Certified. 2023-"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model".-"Venus Remedies Limited Honored with Best Working Conditions Award 2022".-Venus Remedies launched flagship R&D drug Elores in Oman.-Venus Remedies  oncology wing product registrations go up to 506 with marketing approvals from four more countries.-"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities".-'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'. 2023 -"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model". -"Venus Remedies Limited Honored with Best Working Conditions Award 2022". -Venus Remedies has launched its flagship R&D drug, Elores, in the USD 1.4-billion pharmaceutical market in Oman. -"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities.". -'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'. 2024 -Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product. -Venus Remedies awarded with Rs.2.50cr as the remaining part of its first incentive under PLi scheme. -Venus Remedies awarded its first incentive of Rs.7.50 crores under PLI scheme.

M/s VENUS REMEDIES LTD. was incorporated as a private limited company on 15th day of Sept. 1989 in the name and style of Venus Glucose Pvt Ltd, and subsequently converted into a public limited company, vide fresh certificate of incorporation dated 19th Sept. 1994 and the name was converted as "Venus Remedies Ltd" under the Companies Act, issued by the Registrar of Companies, Punjab, Himachal Pradesh and Chandigarh at Jalandhar. The company started its production in the year 1991 with Intravenous/Intramuscular (IV/IM) injectable forms at its running unit located at 52, Ind. Area. Phase-I, Panchkula Distt. Ambala (Haryana). Subsequently the company introduced Eye/Ear/Nasal Drops during the year 1994. During the same year, the company also expanded its existing capacity from 9 lacs pieces per annum to 15 lacs pieces per annum and that of 9 lacs pieces to 20 lacs pieces per annum of IV fluids section and vial section respectively. And, during 1994, the company has also certified as "WHO-GMP" (Good practices in manufacturing and quality control) as specified by WHO, Geneva by the State Drug Controller of Haryana. MAIN OBJECTS OF THE COMPANY The main objects of the company as set out in its Memorandum of Association are : 1. To manufacture, import, export of intravenous transfusion fluids and formations such as dextrose, dextrose with sodium chloride, normal saline, isolate P, isolate M, isolate G, isolate E, Mannitol etc. in various concentrations, intravenous solution for dialysis purposes, ACD Sterile bottles for blood collections, pharmaceutical parenteral preparations like Aminophylline, Adernaline, Water for injection, Chloroquine Sulphate, Sodium bi-carbonate, Analgin, Diazepam, Oxyphenbutazone & other injectables. 2. To carry on the business of deriving, formulating, purchasing, producing manufacturing, preparing, processing, mising, compounding, refining, marketing, distributing, selling and trading in pharmaceuticals, Chemicals, cosmetics, perfumes, medicines and drugs of all kinds, specifications and descriptions, and to do so especially in respect of all kinds of analgesics and antipyretics. 3. To carry on the business of purchasing, producing manufacturing, preparing, processing, mixing, compounding, refining, marketing, distributing, selling and trading in all classes and kinds of raw material ingredients, mixtures, compounds and derivatives connected to, intermediate in or associated with the manufacture production and sale of pharmaceuticals, chemicals medicines and drugs. 4. To carry on the business of vialling, bottling, packing. repacking and processing of capsules, syrups, tablets, injectables, aerosoles and ointment, bulk drugs and chemicals. 2005 -Venus Remedies successfully launches its Brand "Ronem" -Venus Remedies announces Strategic Marketing tie up with M/S Cadila Pharmaceuticals Ltd - M/s Themis Medicare Ltd enters into a Strategic Marketing Tie Up with Venus Remedies Ltd. -Delist equity shares from Delhi, Jaipur & Ahmedabad Stock Exchanges. -Venus Remedies has entered into Strategic Marketing Agreement with Merck Specialties Pvt Ltd, a wholly owned Subsidiary of Merck Ltd, Darmstadt, Germany, for its Oncology range of products. -Venus Remedies sets up a wholly owned subsidiary in Germany 2006 -Venus Remedies Ltd has informed that a Company has been granted three prestigious ISO certifications -Venus Remedies in-licenses product Technology from USA 2007 -Venus Remedies Ltd has signed an agreement with M/s. Pharma Match R&D B.V. a limited Company based at Amsterdam, Netherlands for jointly preparing, registering and marketing an EU E-CTD Dossier for a latest generation Carbapenem Injectible. 2008 -Venus facilities Accredited with European GMP Certification. -Venus Remedies Ltd has informed that the Company's manufacturing facilities have been approved by the G.F.T.O of Syria for manufacturing and exporting its products to Syria. -Venus Remedies - European AMP Accreditation for Venus Oncology Facilities. -Venus Remedies Ltd has informed that the Company has successfully launched its fourth Research Product, a Fixed Dose Combination of Cephalosporin with aminoglycoside under the Brand name "TOBRACEF" in Domestic Market for the first time globally. 2009 -Venus Remedies - Product Patent for "TOBRACEF" granted in South Africa. -Venus Bags Another Product Patent from South Africa for POTENTOX. --Registered Office of the Company has been shifted from SCO 39, Sector 26, Chandigarh. to SCO 857, C. No. 10, IInd Floor, NAC Manimajra, Chandigarh - 160 101. 2010 -Venus Remedies Ltd, a fast-growing pharmaceutical company in the country, has launched MEBATIC, a unique antibiotic combination in infusion form to cure severe gastro intestinal (GI) infections. -"Venus Remedies receives GMP Certification from Botswana". -Venus Remedies ties up with IMTECH and Panjab Univ to develop Typhoid detection kits. -The Company has received approval from the Reserve Bank of India for rollover of FCCB USD 5mn, with YTM @4% with maturity till February 15, 2015. -Venus Remedies research Blockbuster "Sulbactomax" gets European Union Patent". 2011 -"Venus Remedies Anti-Cancer drug "GEMCITABINE" gets UK MHRA approval". -"Sulbactomax" patent from Mexico strengthens Venus Remedies' presence in Latin America". -"Venus Remedies successfully completes Phase I & II Clinical Trials of TUMATREK (VRP162O), cancer detection molecule". -Venus Remedies Ltd wins Gold Medal for TROIS under DST - Lockheed Martin India Innovation Growth Program 2011. -"Venus launches its patented research product ACHNIL" in India". -"Venus Remedies wins "India Manufacturing Excellence Award 2011". 2012 -VenusRemedis - Venus's ACHNIL, BioSpectrum Product of the Year 2012. -VenusRemedis - Innovative Solution for alleviating cancer. -"Venus Remedies introduces "Ready-to-Use" Single Vial Taxedol in India". -Venus Remedies Limited introduced TROIS that is a research based, patent protected topical nano-emulsion product in India -The Company has won Manufacturing Award for its world class manufacturing and operational excellence at the "Industry 2.0 Manufacturing Innovation Conclave 2012". -"Venus wins Patent award in Silver Category". 2013 -"Venus Remedies launches Elores - CSE 1034, a US Patent projected product in India". -"Venus Remedies signs MoU for Elores with South African pharmaceutical firm". -"Venus Remedies takes its flagship product, Elores into Latin America". -"Venus launches its first OTC product Ezenus". -"Venus sign Exclusive Marketing Rights deal for its novel Antibiotic Ajuvant Entity to South Africas second largest Pharmaceutical Company - Adcock". -"Venus Remedies MEROPENEM receives market authorization in Mexico". -Venus Remedies Ltd has informed regarding "ELORES awarded Gold Medal for being the best Innovation of 2013" -"Venus wins Innovative 100 Award for ELORES". -"Venus bags UBM India Pharma Award for Elores". 2014 -"Venus ties up with Mylan for marketing meropenem in three European countries". - "VMRC Drug VRP008 to Fight "MULTI-DRUG Resistant Bacteria" Receives European Patent". -"Venus Receives Market Authorization for Meropenem from SWITZERLAND (SWISSMEDIC)". 2015 -"Venus announces issuance of Indian Patent for Vancoplus". -Venus Remedies holds blood, organ donation camps on its Panchkula premises. 2016 -"Venus launches its second OTC product "SWATCH GAURD" a herbal Hand Sanitizer". 2019 -"Venus announces deal with Cipla for its patented product Elores for Indian Territory". 2021 -Venus Remedies launched its full-fledged Consumer Healthcare Division. -Venus Remedies Limited has been selected for Production Linked Incentive Scheme (PLI) of the Government of India. 2022 -Venus Remedies won WHO Good Distribution Practices (GDP) certification for quality services across entire supply chain. -Venus remedies wins ambitionbox best places to work award. -Venus Remedies Limited has been Great Place to Work Certified. 2023-"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model".-"Venus Remedies Limited Honored with Best Working Conditions Award 2022".-Venus Remedies launched flagship R&D drug Elores in Oman.-Venus Remedies  oncology wing product registrations go up to 506 with marketing approvals from four more countries.-"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities".-'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'. 2023 -"Venus Earns Prestigious FICCI Healthcare Award 2023 for Pioneering 'Organ-on-a-Chip' Research Model". -"Venus Remedies Limited Honored with Best Working Conditions Award 2022". -Venus Remedies has launched its flagship R&D drug, Elores, in the USD 1.4-billion pharmaceutical market in Oman. -"Venus Remedies Awarded Ukrainian GMP Approval for Its Carbapenem, Oncology Parenteral Facilities.". -'Venus Remedies awarded Saudi GMP approval for all its production facilities in Baddi.'. 2024 -Venus Remedies achieves major milestone with UNICEF by securing the prestigious tender for its antibiotic product. -Venus Remedies awarded with Rs.2.50cr as the remaining part of its first incentive under PLi scheme. -Venus Remedies awarded its first incentive of Rs.7.50 crores under PLI scheme.

Read More

Parent Organisation

Venus Remedies Ltd.

Founded

15/09/1989

Managing Director

Mr.Pawan Chaudhary

NSE Symbol

VENUSREMEQ

FAQ

The current price of Venus Remedies Ltd is ₹ 290.40.

The 52-week high for Venus Remedies Ltd is ₹ 294.65 and the 52-week low is ₹ 289.90.

The market capitalization of Venus Remedies Ltd is currently ₹ 388.18. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Venus Remedies Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Venus Remedies Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Venus Remedies Ltd shares.

The CEO of Venus Remedies Ltd is Mr.Pawan Chaudhary, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT